12/23
06:30 am
zura
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Low
Report
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
12/11
11:29 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Neutral
Report
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/25
06:30 am
zura
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
11/18
08:09 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/14
04:30 pm
zura
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
High
Report
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
11/11
10:22 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/11
08:10 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $14.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Zura Bio Limited (NASDAQ: ZURA) had its price target lowered by analysts at Chardan Capital from $14.00 to $12.00. They now have a "buy" rating on the stock.
11/7
06:30 am
zura
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Medium
Report
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
11/5
08:19 am
zura
Zura Bio Limited (NASDAQ: ZURA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Zura Bio Limited (NASDAQ: ZURA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
11/4
08:19 am
zura
Zura Bio Limited (NASDAQ: ZURA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
Medium
Report
Zura Bio Limited (NASDAQ: ZURA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $15.00 price target on the stock.
10/30
06:30 am
zura
Zura Bio to Participate in Two Upcoming Investor Conferences in November
Low
Report
Zura Bio to Participate in Two Upcoming Investor Conferences in November
10/21
08:07 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/18
08:33 am
zura
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.